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Abstract
Background: HPV16 variants are associated with different risks for development of CIN3 and invasive cancer,
although all are carcinogenic. The relationship of HPV 16 variants to cancer survival has not been studied.
Methods: 155 HPV16-positive cervical cancers were categorized according to European and non-European variant
patterns by DNA sequencing of the E6 open reading frame. Clinico-pathologic parameters and clinical outcome
were collected by chart review and death registry data.
Results: Of the 155 women (mean age 44.7 years; median follow-up 26.7 months), 85.2% harbored European
variants while 14.8% had non-European sequences. HPV16 variants differed by histologic cell type (p = 0.03) and
stage (1 vs. 2+; p = 0.03). Overall, 107 women (68.0%) were alive with no evidence of cancer, 42 (27.1%) died from
cervical cancer, 2 (1.3%) were alive with cervical cancer, and 4 (2.6%) died of other causes. Death due to cervical
cancer was associated with European variant status (p < 0.01). While 31% of women harboring tumors with
European variants died from cervical cancer during follow-up, only 1 of 23 (4.4%) non-European cases died of
cancer. The better survival for non-European cases was partly mediated by lower stage at diagnosis.
Conclusions: Overall, invasive cervical cancers with non-European variants showed a less aggressive behavior than
those with European variants. These findings should be replicated in a population with more non-European cases.
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Background
While the association of HPV genotypes and cervical
carcinoma is well established, the reasons that only a
subset of lesions associated with high-risk genotypes
progress to invasive cancer remain elusive. Influential
variables likely include individual host factors, viral dif-
ferences or combinations of both.
One variable that could contribute to differences in
biological behavior of HPV- associated lesions is that of
HPV DNA sequence variation. HPV16, which is the
most prevalent HPV genotype and is associated with
approximately half of cervical cancers worldwide [1], has
well-documented DNA sequence variants. HPV variants
are defined as isolates with primary DNA sequence dif-
ferences that total no more than 2% of the L1 open
reading frame (ORF) of the prototype sequence [2]. The
sequence variations of the HPV16 E6 ORF have been
found to correctly classify the HPV16-variants [3]. Two
major categories of HPV16 variants have been defined:
European (E) and Non-European (NE) patterns that
appear to have evolved principally on a geographic basis
[4]. A number of studies have suggested that HPV16
variants differ in risk for progression to high grade
intraepithelial lesions [5-7] and in their association with
the development of cancer [8-12]. Overall, the 16-NE
variants have shown an increased risk for progression to
CIN2 or greater when compared with 16-E.
We have previously reported the patterns of HPV16
variants in the spectrum of cervical lesions in our popu-
lation [11]. While our study confirmed the increased
risk for progression to carcinoma associated with 16-NE
v a r i a n t s ,1 6 - Ep a t t e r n sw e r ef o u n di nt h em a j o r i t yo f
HPV16 lesions, including cancers. We attributed this to
the dominance of the 16-E patterns in our population
* Correspondence: rosemary-zuna@ouhsc.edu
1Department of Pathology, University of Oklahoma Health Sciences Center,
940 SL Young Blvd, Oklahoma City, Oklahoma, 73104-5042, USA
Full list of author information is available at the end of the article
Zuna et al. Infectious Agents and Cancer 2011, 6:19
http://www.infectagentscancer.com/content/6/1/19
© 2011 Zuna et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.and to the fact that all major variant categories can be
found in cancers.
In this follow-up study, we address the question of
whether HPV16 variant status influences clinical pat-
terns and/or prognosis in fully evolved cervical cancers.
We performed a cross-sectional analysis of the clinico-
pathologic characteristics of an unselected, prospectively
accumulated population of women with HPV16-positive
invasive cervical cancer from the central United States.
The tumors were categorized according to histologic
cell type and HPV16 variant category. We also corre-
lated the clinico-pathologic characteristics and clinical
follow-up with HPV16-variant category in an effort to
evaluate the possible association of the HPV16 variants
with clinical behavior in cervical cancers.
A similar analysis was performed for the largest sub-
population, i.e., HPV16-positive squamous cell cancers
harboring European variants, in an effort to identify dif-
fering patterns of biologic behavior within sub-lineages
of this dominant category.
Results
Patient Demographics
The population of 155 women with HPV16- associated
cancers had a mean age of 44.7 years ± 1.0 (SEM), ran-
ging from 20-76 years. Median follow-up was 26.7 ±
24.5 months (mean = 31.5 ± 2.0 months). Overall, 107
women (68.0%) were alive with no evidence of cancer,
42 (27.1%) died from cervical cancer, 2 (1.3%) were alive
with cervical cancer, and 4 (2.6%) had died of other
causes. Of these cases, 132 (85.2%) harbored 16-E var-
iants while 23 (14.8%) had 16-NE patterns (AA = 17
cancers, NA-1 = 3, AF1 and AF2 = 3). The patient char-
acteristics for this population, sorted according to var-
iant status, are summarized in Table 1.
Clinico-pathologic variables
Of 149 women with definite clinical outcome, the
overwhelming majority, 91.3%, were diagnosed with
SCC. 16-E variants were identified in 119 (87.5%) SCC
lesions. These accounted for 93.7% of all 16-E variant
cases in this population. Although SCC cancers har-
boring 16-E variants dominated in this population, and
16-E cases were more frequent in all other histologic
categories as well, the percentage of 16-NE variants
r a n g e df r o m4 4 . 4 %( 4o f9 )o fC A Cc o m p a r e dw i t h
25% (1 of 4) for ASC and 12.5% (17 of 136) for SCC.
The distribution of individual 16-NE variant categories
for histologic cell type is as follows: AA = 12 SCC and
4 CAC; NA-1 = 3 SCC; AF1 = 1 SCC and AF2 = 1
SCC and 1 ASC. Despite the disparity in case numbers,
the differences in the distribution of HPV16-variants
among the histologic cell types were statistically signif-
icant (p = 0.03).
There was no significant difference in the distribution
of HPV16 variants according to tumor size, depth of
invasion, vascular space invasion, lymph node involve-
ment, parametrial involvement, or status of surgical
margins. Similarly, none of the clinical parameters
showed a significant difference associated with 16-var-
iant status including race/ethnicity, age group, FIGO
stage and number of pregnancies.
Although significant differences were not identified
between the 16-E and 16-NE variant groups for the
above prognostic variables affecting survival in cervical
cancer patients, there were interesting trends among 16-
NE cases for some parameters that may reveal signifi-
cance in a larger study with a larger population of 16-
NE cases. These variables include younger age, early
stage at presentation, three or fewer pregnancies, race/
ethnicity other than white, depth of stromal invasion
greater than 5 mm, and the presence of lymphovascular
space invasion for 16-NE patients. While not statistically
significant (ptrend = 0.13), the modal peak for 16-NE
cases was the 31-40 age group (mean = 41.4 ± 2.6 years;
median 38 years) compared with the 41-50 group for
the 16-E cases (mean = 45.3 ± 1.0; median 45 years).
Figure 1 illustrates that the majority of women with 16-
NE lesions presented at stage IB1 while those with 16-E
lesions presented at a more variable stage (ptrend = 0.02).
Because of the uneven distribution of cases in this
study, a second analysis was performed that was
restricted to the 123 cases of SCC associated with Eur-
opean variants. This population had a mean age of
45.9 years ± 1.1 (SEM), ranging from 20 to 76 years of
age. Median follow-up was 28 months ± 22.4 (mean
33.0 ± 2.0). This population was divided into three
categories as follows based on subgroups of European
variants: European prototype (16-EP) (N = 53), Eur-
opean variants with a small number of nucleotide
changes compared to prototype (16-EV) (N = 21), and
those European variants harboring the 350 T>G
nucleotide change (N = 49).
The 16-EV category has been previously described
[11] and is similar to the European prototype with the
addition of one or more single nucleotide changes. In
this report, we subdivided the 16-EV category into two
groups based on the presence or absence of the com-
mon 350T>G nucleotide change. In the first, termed 16-
EV here, the nucleotide pattern differed from prototype
by one nucleotide alteration. The location of the nucleo-
tide change was variable and only the 178 T>G (some-
times termed the As variant) alteration (n = 4) was
found in more than one case. The second pattern (16-
EV-G) was defined by the presence of the European 350
T>G alteration as a single nucleotide change or with a
small number of additional single nucleotide changes
[11]. For example, three cases in this group showed a
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Page 2 of 9Table 1 Clinicopathologic Features of 149 Cervical Cancer Cases
TRAIT CATEGORY EUROPEAN (%
1)
n = 127
NON EUROPEAN (%
1)
n=2 2
TOTAL (%
2) P-VALUE
3
n = 149
Squamous Carcinoma 119 (87.5) 17 (12.5) 136 (91.3)
CELL TYPE Adenocarcinoma 5 (55.6) 4 (44.4) 9 (6.0) 0.03
Adenosquamous Ca 3 (75.0) 1 (25.0) 4 (2.7)
AGE GROUP 20-40 46 (78.0) 13 (22.0) 59 (39.6)
(YEARS) 41-50 46 (92.0) 4 (8.0) 50 (33.6) 0.13
51-72 35 (87.5) 5 (12.5) 40 (26.8)
White 102 (88.7) 13 (11.3) 115 (77.7)
RACE Black 4 (80.0) 1 (20.0) 5 (3.4) 0.11
Hispanic 7 (63.6) 4 (36.4) 11 (7.4)
Native American 10 (71.4) 4 (28.6) 14 (9.5)
Asian 2 (100) 0 2 (1.4)
Other 1 (100) 0 1 (0.7)
Unknown 1 - - 1 -
1A 14 (87.5) 2 (12.5) 16 (11.1)
STAGE (FIGO) 1B1 42 (75.0) 14 (25.0) 56 (38.9) 0.16
1B2 16 (88.9) 2 (11.1) 18 (12.5)
2 22 (91.7) 2 (8.3) 24 (16.7)
3 18 (94.7) 1 (5.3) 19 (13.2)
4 11 (8.9) 0 11 (7.6)
Recurrent/Unstaged 4 - 1 - 5 -
0 6 (85.7) 1 (14.3) 7 (4.9)
GRAVIDITY 1-3 73 (82.0) 16 (18.0) 89 (61.8) 0.13
>3 45 (93.8) 3 (6.3) 48 (33.3)
ND
4 3- 2- 5-
PARAMETRIA
5 Negative 53 (77.9) 15 (22.1) 68 (60.7) 0.12
Positive 40 (90.9) 4 (9.1) 44 (39.3)
ND 34 - 3 - 37 -
Table 1 (cont’d)
<1 16 (84.2) 3 (15.8) 19 (14.6)
TUMOR SIZE
5 (cm) 1-4 42 (76.4) 13 (23.6) 55 (42.3) 0.1
>4 51 (91.1) 5 (8.9) 56 (43.1)
ND 18 - 1 - 19 -
< 3 15 (93.8) 1 (6.3) 16 (19.3)
INVASION DEPTH
6 3.1 - 5.0 10 (83.3) 2 (16.7) 12 (14.5) 0.21
(mm) >5 40 (72.7) 15 (27.3) 55 (66.3)
ND 62 - 4 - 66 -
Positive 40 (74.1) 14 (25.9) 54 (62.1)
VSI
6 Negative 29 (87.9) 4 (12.1) 33 (37.9) 0.17
ND 58 - 4 - 62 -
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Page 3 of 9Table 1 Clinicopathologic Features of 149 Cervical Cancer Cases (Continued)
RESECTION Positive 11 (91.7) 1 (8.3) 12 (14.6)
MARGINS
6 Negative 53 (75.7) 17 (24.3) 70 (85.4) 0.29
ND 63 - 4 - 67 -
LYMPH NODES
7 Negative 48 (85.7) 8 (14.3) 56 (50.4)
Positive 44 (80.0) 11 (20.0) 55 (49.6) 0.46
ND 35 - 3 - 38 -
NED 86 (80.4) 21 (19.6) 107 (71.8)
STATUS
8 DOD 41 (97.6) 1 (2.4) 42 (28.2) 0.008
1: Percentage calculated across.
2: Percentage calculated down.
3: Fisher’s Exact Test
4: ND: No data available
5: Parametrial assessment and tumor size were determined by pathologic analysis of a radical hysterectomy or as part of a clinical staging procedure.
6: Depth of invasion, margin status and status of vascular space invasion were available only for women with early stage tumors who had a conization or
hysterectomy.
7: Lymph node dissections were routinely performed as part of radical hysterectomy. It is not standard for higher stage women although cervical biopsy with
lymph node dissection was performed for some higher stage women.
8: Status: NED = No evidence of cervical cancer at last follow-up; DOD = Dead of cervical cancer
Figure 1 Distribution of FIGO stage for women presenting with cervical carcinoma according to 16-variant status.
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Page 4 of 9131A>G change in addition to 350T>G. Because of the
frequency of the 350T>G pattern, this group of 16-EV
tumors was analysed separately in this study in an effort
to clarify the clinical significance of this change. The 16-
EV-G category specifically excludes the 16-NE variants
that contain this same nucleotide 350 alteration. The
clinico-pathologic character i s t i c so ft h i sp o p u l a t i o na r e
shown in Table 2.
Cross-sectional analysis restricted to the subgroup of
123 women with SCC harboring European variants
failed to demonstrate significant differences among the
various clinical and patholog i ct r a i t sf o rt h ed i f f e r e n t
variant categories (Table 2). The 16-EP and 16-EV-G
categories had similar characteristics. The 16-EV group
was somewhat divergent but the numbers were small
and the differences not significant. A comparison of 16-
EV-G cases relative to all other 16-E SCC also showed
no significant differences (data not shown).
Clinical Follow-up
After a median follow-up of 29.1 months ± 23.3, death
due to cervical cancer was highly associated with 16-E
variant status (p < 0.01). While 31% (41/127) of women
harboring tumors with 16-E variants died from cervical
cancer, only 1 of 23 (4.4%) 16-NE cases died of cervical
cancer. There were no differences in follow-up status or
total follow-up time within the subgroups of 16-E squa-
mous cancers.
We attempted to explain the survival differences by
adjustment (by stratification or restriction) for possible
Table 2 Clinicopathologic Features of 119 HPV16-Positive Squamous Cell Carcinoma Cases with European Variants
TRAIT CATEGORY 16-EP (%
1)
n=5 2
16-EV (%
1)
n=2 0
16-EV-G (%
1)
n=4 7
Total (%
2)
n = 119
P-VALUE
3
Non-keratinizing 26 (41.9) 12 (19.4) 24 (38.7) 62 (57.4)
CELL TYPE Keratinizing 21 (45.7) 5 (10.9) 20 (43.5) 46 (42.6) 0.53
Squamous, NOS
4 5- 3- 3- 1 1-
AGE GROUP 20-40 15 (37.5) 5 (12.5) 20 (50.0) 40 (33.6)
41-50 20 (45.5) 11 (25.0) 13 (29.5) 44 (37.0) 0.26
51-72 17 (48.6) 4 (11.4) 14 (40.0) 35 (29.4)
RACE White 44 (45.8 15 (15.6) 35 (38.5) 94 (76.1)
Black 2 (50.0) 2 (50.0) 0 4 (3.4) 0.07
Hispanic 2 (28.6) 0 5 (71.4) 7 (5.9)
Native American 3 (30.0) 1 (10.0) 6 (60.0) 10 (8.5)
Asian 1 (50.0) 1 (50.0) 0 2 (1.7)
Other 0 - 1 (100) 0 1 (0.8)
ND
5 0- 0- 1- 1-
1A 6 (42.9) 2 (14.3) 6 (42.9) 14 (12.2)
STAGE (FIGO) 1B1 16 (44.4) 8 (22.2) 12 (33.3) 36 (31.3) 0.75
1B2 4 (28.6) 3 (21.4) 7 (50.0) 14 (12.2)
2 10 (45.5) 1 (4.5) 11 (50.0) 22 (19.1)
3 9 (50.0) 3 (16.7) 6 (33.3) 18 (15.6)
4 5 (45.5) 3 (27.3) 3 (27.3) 11 (9.6)
Recurrent/Unstaged 2 - 0 - 2 - 4 -
0 4 (80.0) 0 - 1 (20.0 5 (4.3)
GRAVIDITY 1-3 24 (35.8) 11 (16.4) 32 (47.8) 67 (57.8) 0.18
>3 22 (50.0) 9 (20.5) 13 (29.5) 44 (37.9)
ND
5 2- 0- 1- 3-
PARAMETRIA
6 Negative 20 (43.5) 8 (17.4) 18 (39.1) 46 (53.5)
Positive 19 (47.5) 6 (15.0) 15 (37.5) 40 (46.6) 0.92
ND 13 - 6 - 14 - 33 -
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Page 5 of 9factors such as stage at diagnosis or age, which showed
a relationship both to variant status and outcome. Even
within Stage 1 cancers, however, for which survival was
favorable, tumors with 16-E variants tended to have
somewhat worse outcomes than those with 16-NE var-
iants (data not shown).
Discussion
The rationale behind the possibility of biological differ-
ences associated with variant status is related to altera-
tions in primary HPV DNA sequence that may alter
control elements or affect the function of translated pro-
teins that interact with the host. For example, the most
common E6 sequence variation from prototype
described in the 16-E-variants is 350 T> G that results
in a L83V amino acid change in the E6 protein. Such
amino acid changes can potentially alter tertiary struc-
ture and may influence protein function. In vitro studies
of different HPV16-variants have suggested differences
in biological activity [13], but an in vivo mechanism of
enhanced biological activity has not been described. To
date, evidence for different biological effects related to
the sequence variants in patients has accumulated on an
epidemiologic basis.
The increased risk for progression of 16-NE cervical
lesions to high grade CIN and carcinoma has been
attributed in part to reports that 16-NE variants are
associated with a higher rate of HPV16 persistence and
development of high-grade intraepithelial cervical lesions
[6,7]. In this report, we explored the question of
Table 2 Clinicopathologic Features of 119 HPV16-Positive Squamous Cell Carcinoma Cases with European Variants
(Continued)
Table 2 (cont’d)
<1 6 (40.0) 2 (13.3) 7 (46.7) 15 (14.7)
TUMOR SIZE
6 (cm) 1-4 18 (46.2) 7 (17.9) 14 (35.9) 39 (38.2) 0.96
>4 21 (43.8) 7 (14.6) 20 (41.7) 48 (47.1)
N D 7- 4- 6- 1 7-
< 3 3 (23.1) 2 (15.4) 8 (61.5) 13 (22.0)
INVASION DEPTH
7 3.1 - 5.0 5 (62.5) 0 3 (37.5) 8 (13.3) 0.24
(mm) >5 19 (50.0) 7 (18.4) 12 (31.6) 38 (64.4)
ND 25 - 11 - 24 - 60 -
Positive 15 (40.5) 6 (16.2) 16 (43.2) 37 (59.7)
VSI
7 Negative 12 (48.0) 3 (12.0) 10 (40.0) 25 (40.3) 0.83
ND 25 - 11 - 21 - 57 -
RESECTION Positive 7 (63.6) 1 (9.1) 3 (27.3) 11 (19.3)
MARGINS
7 Negative 19 (41.3) 8 (17.4) 19 (41.3) 46 (80.7) 0.49
ND 26 - 11 - 25 - 65 -
Negative 20 (47.6) 4 (9.5) 18 (42.9) 42 (49.4)
LN STATUS
8 Positive 18 (41.9) 8 (18.6) 17 (39.5) 43 (50.6) 0.55
ND 14 - 8 - 12 - 34 -
NED 34 42.5) 13 (16.3) 33 (41.3) 80 (67.2)
STATUS
9 DOD 18 46.2) 7 (17.9) 14 (35.9) 39 (32.8) 0.87
1: Percentage calculated across.
2: Percentage calculated down.
3: Fisher’s exact test
4: Squamous, NOS: Women with very small tumors or tiny biopsies were difficult categorize as to cell type and were not included in these analyses.
5: ND: No data available
6: Tumor size and parametrial assessment were determined by pathologic evaluation of a radical hysterectomy or as part of a clinical staging procedure.
7: Depth of invasion, margin status and status of vascular space invasion were available only for women with early stage tumors who had a conization or
hysterectomy.
8: Lymph node dissections were routinely performed as part of radical hysterectomy. It is not standard for higher stage women although cervical biopsy with
lymph node dissection was performed for some higher stage women.
9: Status: NED = No evidence of cervical cancer; DOD = Dead of cervical cancer
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Page 6 of 9whether this increased risk for progression associated
with 16-NE variants also correlates with increased
aggressiveness of fully evolved invasive cancers. Our
data for 155 HPV16-positive cervical cancer cases fol-
lowed for a median of 29.1 months does not support
this hypothesis. In fact, the women with tumors harbor-
ing 16-E variants had a statistically increased risk of
death due to cervical cancer. A major problem in inter-
preting these results, however, is the skewed pattern of
our cases, with strong predominance of squamous can-
cers and 16-E patterns. This imbalance could mask any
possible difference in the behavior associated with the
16-NE lesions. For example, 16-NE variants, particularly
the AA variant, have been reported to be associated
with CAC [9,10] which have a more aggressive course
than SCC in some reports [14,15]. In this population,
however, only 14 (9.0%) HPV16-positive cases were
CAC or ASC.
Survival in cervical cancer patients is related primarily
to stage at diagnosis, tumor size, depth of cervical stro-
mal invasion, parametrial involvement, lymphovascular
space invasion, and lymph node status [16]. Histologic
cell type [17] as well as HPV genotype, especially
HPV18 [18] have also been reported as prognostic
factors.
While survival in this study was correlated with 16-E
variant status, there are clues to suggest that this may
be an overly simplistic impression given the dispropor-
tionate number of cases in the two groups. In this study
most of the 16-NE cancer patients presented at a young
age and at an early stage (1B1). Additionally, these data
showed non-significant trends in which 16-NE lesions
had larger size at presentation with increased rate of
vascular space invasion and lymph node metastases. It is
therefore conceivable that the small number of 16-NE
lesions in this population has resulted in a non-repre-
sentative distribution of cases. Similarly, it is not clear
whether this pattern is representative of all 16-NE cases
or if our population is simply anomalous due to small
numbers of 16-NE cases. Conceivably, our young 16-NE
cases represent a detection bias in which younger
women with cancer were identified because of screening
while the older 16-E population presented with signs
and symptoms of cancer. The relatively small proportion
of 16-NE cases could thus result in anomalous results.
On the other hand, these results raise the possibility
that 16-NE variants have a preferential role in progres-
sion to malignancy but do not differentially influence
clinical behavior in fully evolved cancers. When we ana-
lyzed a subpopulation of cancer cases representing the
dominant group of HPV16 European sequence patterns,
we were unable to show a difference in clinical behavior
based on subcategories of 16-E variants.
Conclusions
While our earlier study showed a significant association
of 16-NE variant status with progression to high grade
CIN and invasive cancer in cases with a wide spectrum
of cervical disease[11], we have not been able demon-
strate more aggressive behavior for actual invasive carci-
nomas associated with these variants. These results,
however, should be interpreted with caution due to the
limited number of 16-NE cases in this population. A lar-
ger study with a larger population of 16-NE cases is
needed to clarify these issues.
Methods
Patient Population
From 1999-2009, 319 unselected cases of primary, meta-
static and recurrent invasive cervical carcinoma were
prospectively entered into this study based on the col-
lection of a liquid-based cytologic sample that was
tested for HPV DNA and a histologic diagnosis of inva-
sive cervical cancer. The population seen at our institu-
tion is variably screened for cervical cancer so that some
cancer patients were identified by routine screening
while others presented with clinical signs and symptoms
related to cervical cancer. Included in this total were
164 cases from the SUCCEED study [19] and 85 cases
that were included in previous reports [20]. These
women were staged according to FIGO (International
Federation of Gynecology and Obstetrics, 2000) and
treated at the OU Medical Center in Oklahoma City
using standard therapies of surgery, radiation, and che-
motherapy as indicated by individual patient characteris-
tics. Of the 167 HPV16-positive cancer cases, 155 were
available for variant analysis. Because 80 (51.6%) women
did not undergo total hysterectomy and 40 (25.8%) did
not have a lymphadenectomy, some pathologic variables
were not evaluable in all cases. Follow-up was deter-
mined by chart review and death records for the state of
Oklahoma. In addition to clinico-pathologic parameters,
we compared over-all follow-up taking into account
clinical stage at diagnosis, race, age, and censoring due
to loss-to-follow-up. Statistical analyses reported below
were performed using the population of women (n =
149) with defined outcome (i.e., no evidence of disease
or dead of cervical cancer). This study was performed
with the approval of the Institutional Review Board for
the University of Oklahoma Health Sciences Center.
Pathologic Categorization
All cancer diagnoses were confirmed histologically and
the cell type was determined using routine hematoxylin
and eosin staining supplemented by any special stains
performed at the time of initial diagnosis. The tumor
cell types were categorized using standard histologic
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Page 7 of 9criteria [21]. Squamous cell carcinomas (SCC) were
designated as “large cell keratinizing” when at least one
well-formed keratin pearl was identified [22] and “large
cell non-keratinizing” when no pearls were identified.
Squamous tumors that were very small or for which
only small biopsies were available, were listed as “SCC,
not otherwise specified”.
The major histologic categories included SCC (n =
141), both keratinizing and non-keratinizing patterns,
adenocarcinoma (CAC) (n = 10), and adenosquamous
carcinoma (ASC) (n = 4). There were no HPV16-posi-
tive small cell neuroendocrine carcinomas in this
population.
HPV Testing Using L1 Consensus Primers
Liquid-based cytologic samples were collected in Pre-
servCyt
® (Hologic, Malborough, MA) at the time of
clinical evaluation and the cellular DNA was extracted
using the QIAamp
® DNA Blood and Tissue Mini Kit
(Qiagen, Valencia, CA). HPV genotyping was performed
using the reverse line blot/Linear Array
® HPV Genotyp-
ing Test (Roche Molecular Systems, Alameda, CA), as
previously described [20].
Variant Analysis
Aliquots of cellular DNA from HPV16-positive tumor
samples were analyzed for HPV16 E6 variant category
using PCR amplification and bidirectional PCR-based
fluorescent dideoxy chain termination sequencing using
the same primers used for initial amplification, as pre-
viously described [11].
Sequence alignments were performed using CLUS-
TALW [23]. Only nucleotide changes verified as occur-
ring on both strands were accepted.
An HPV16-variant category was assigned for each case
using the prototype nucleotide sequence for HPV16 [24]
(modified as HPV16R [25]) as well as published HPV16
E6 sequence patterns that define the different variants
[3]. The 16-E category included the prototype sequence
and related patterns showing only a small number of
nucleotide changes, while the 16-NE categories included
Asian-American (AA), Native-American (NA-1), and
African (AF-1 and AF-2).
In the secondary analysis restricted to 16-E SCC cases,
the variants were subdivided into 16-EP (prototype), 16-
EV (European prototype sequence with a small number
of additional nucleotide differences), and 16-EV-G (Eur-
opean sequence with the common 350T>G substitution;
cases with nucleotide changes in addition to 350T>G
were also included).
Statistics
Tabular analyses were performed using chi square and
Fisher’s exact and Cochran-Mantel-Haenszel trend tests.
Statistical significance was assigned to 2-sided probabil-
ity values < .05.
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